Stemrim Secures Korean Patent for Epidermolysis Bullosa Treatment Technology SR-GT1

TOKYO, Jul 08 (Pulse News Wire) – StemRIM Inc. (4599.T) announced the registration of a patent related to its stem cell gene therapy technology (development code: SR-GT1) aimed at treating epidermolysis bullosa caused by nutritional deficiencies.

The patent application number is 10-2021-7,025,601 and was filed in South Korea. This technology involves cultivating mesenchymal stem cells taken from blisters of patients with epidermolysis bullosa and introducing normal VII-type collagen genes efficiently. After further cultivation, these genetically modified cells are re-administered back into the patient's blisters to ensure long-term stable supply of VII-type collagen, aiming for a curative treatment. The newly secured patent covers the aspect of administering cells into the patient’s blisters within South Korea. Epidermolysis bullosa is a genetic disorder characterized by the formation of burns-like blisters and ulcers due to minor external forces.

Currently, there is no curative treatment available for this condition. StemRIM has been developing this technology alongside Osaka University, supported by the Japan Agency for Medical Research and Development (AMED). Clinical trials are underway, and preparations for transitioning to physician-led trials are progressing steadily. There will be no impact on StemRIM's fiscal year ending July 2026 results from this patent registration. However, the company will promptly disclose any significant developments arising from this patent.